IMR Press / JIN / Volume 20 / Issue 2 / DOI: 10.31083/j.jin2002025
Open Access Original Research
The effects of Danggui-Shaoyao-San on neuronal degeneration and amyloidosis in mouse and its molecular mechanism for the treatment of Alzheimer’s disease
Show Less
1 Science and Technology Innovation Center, Guangzhou University of Chinese Medicine, 510405 Guangzhou, Guangdong Province, China
2 Institute of Clinical Pharmacology, Guangzhou University of Chinese Medicine, 510405 Guangzhou, Guangdong Province, China
3 Xi’an Hospital of Traditional Chinese Medicine, 710021 Xi’an, Shaanxi Province, China
*Correspondence: (Qun Du); (Qi Wang)
These authors contributed equally.
J. Integr. Neurosci. 2021, 20(2), 255–264;
Submitted: 30 September 2020 | Revised: 6 December 2020 | Accepted: 1 February 2021 | Published: 30 June 2021
Copyright: © 2021 The Author(s). Published by IMR Press.
This is an open access article under the CC BY 4.0 license (

The abnormal deposition of the extracellular amyloid-β peptide is the typical pathological hallmark of Alzheimer’s disease. Strategies to reduce the amyloid-β deposition effectively alleviate the neuronal degeneration and cognitive deficits of Alzheimer’s disease. Danggui-Shaoyao-San has been considered a useful therapeutic agent known for the treatment of Alzheimer’s disease. However, the mechanism of Danggui-Shaoyao-San for the treatment of Alzheimer’s disease remains unclear. We investigated Danggui-Shaoyao-San’s effect on amyloidosis and neuronal degeneration in an APP/PS1 mouse model. We found Danggui-Shaoyao-San alleviated the cognitive deficits in APP/PS1 mice. Additionally, Danggui-Shaoyao-San ameliorated the neuronal degeneration in these mice. Danggui-Shaoyao-San reduced the amyloidosis and amyloid-β1-42 deposition in APP/PS1 mouse brain and down-regulated the receptor for advanced glycation end products, and up-regulated the level of low-density lipoprotein receptor-related protein-1. However, the protein expression of the β-amyloid precursor protein, β-Secretase and presenilin-1 (PS1) in the amyloid-β production pathway, and the expression of neprilysin and insulin-degrading enzyme in the amyloid-β degradation pathway were not altered. Our findings collectively suggest that Danggui-Shaoyao-San could ameliorate the amyloidosis and neuronal degeneration of Alzheimer’s disease, which may be associated with its up-regulation lipoprotein receptor-related protein-1 and down-regulation of the receptor for advanced glycation end products.

Alzheimer's disease
Cognitive deficits
Lipoprotein receptor-related protein-1
Fig. 1.
Back to top